PublicWire | Emerging Market Stock News
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
No Result
View All Result
PublicWire
No Result
View All Result

Home » Cannabis » Vitality Biopharma Files Intellectual Property in All Major Pharmaceutical Markets Worldwide

Vitality Biopharma Files Intellectual Property in All Major Pharmaceutical Markets Worldwide

by Tony Allen
April 26, 2019
in Cannabis, Medical
Reading Time: 3 mins read
0
  • THC prodrugs including VBX-100 designed to deliver cannabinoids for targeted therapeutic effects without psychoactivity

LOS ANGELES, March 28, 2018 (GLOBE NEWSWIRE) — Vitality Biopharma, Inc. (OTCQB:VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced the filing of its cannabosides intellectual property (Publ. No. WO2017053574 A1) in all major pharmaceutical markets worldwide.

After initial submission through the Patent Cooperation Treaty (PCT), an international patent law treaty that provides a unified filing process for 151 countries, Vitality Biopharma has now begun submission for its patent applications in the U.S., Europe, Japan, and additional key regions.  Upon patent grant, coverage of underlying patent claims would extend to at least 2035, and ensure intellectual property protection in all major pharmaceutical markets worldwide.

The filings include “composition of matter” patent claims covering Vitality’s THC prodrugs and lead drug candidate VBX-100, a gut-targeted cannabinoid pharmaceutical.  VBX-100 and the Company’s prodrug technology enables large concentrations of cannabinoids to be selectively delivered to the intestinal tract with limited entry into the bloodstream or brain.  As a result, Vitality’s prodrugs may provide targeted relief of Crohn’s disease and other digestive disorders, providing therapeutic effects without any psychoactivity.

“We are excited to initiate patent prosecution in the U.S. and global pharmaceutical markets, where we are seeking broad patent coverage for VBX-100 and the entire portfolio of cannabosides,” said Dr. Brandon Zipp, Director of R&D, and Scientific Co-founder of Vitality Biopharma.  Robert Brooke, the Company’s CEO, adds that, “Today, Vitality is positioned very well for growth, as we have a highly differentiated and proprietary set of compounds that could dramatically alter the quality-of-life for patients.”

About Vitality Biopharma (OTCQB: VBIO)
Vitality Biopharma is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. For more information, visit: www.vitality.bio. Follow us on Facebook, Twitter and LinkedIn.

Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Contact                                                                                               
Vitality Biopharma 
Investor Relations
info@vitality.bio
1-530-231-7800
www.vitality.bio

Tags: cannabinoidsinflammatory disordersneurologicalVBIOVitality Biopharma
Previous Post

Arizona Silver Acquires New Gold-Silver Exploration Property in Southeastern Arizona

Next Post

Precision Therapeutics Announces Record STREAMWAY® System Sales in the First Three Months of 2018

Tony Allen

Tony Allen received a bachelor’s degree in journalism from the University of South Florida in 2011, specializing in feature writing and reporting on sports and events.

Related Posts

Medical

FDA advisory panel recommends Moderna, Johnson & Johnson vaccine booster shots

October 18, 2021
0
Medical

Walgreens invests $5.5B to accelerate new healthcare business segment

October 18, 2021
0
Medical

Mayo Clinic to study respiratory muscle training as long COVID treatment

October 18, 2021
0
Medical

Anthem, Providence tap Vim for value-based care platform deployment

October 25, 2021
0
Medical

Healthcare lost 17,500 jobs in September amid ongoing labor shortage

October 25, 2021
0
Medical

Cigna divests life, accident and supplemental benefits businesses for $5.75B

October 25, 2021
0
Next Post

Precision Therapeutics Announces Record STREAMWAY® System Sales in the First Three Months of 2018

Please login to join discussion

Subscribe To Our Newsletter

Loading
Ad
PublicWire | Emerging Market Stock News 24/7 | Investor Relations US Stock Market

© Copyright 2022 publicwire.com

Navigate Site

  • About
  • Contact Us
  • Disclaimer
  • Watch LIVE
  • Privacy Policy
  • Terms and Services
  • Contributors

Follow Us

No Result
View All Result
  • LIVE Investor News Channel
  • Cannabis
  • Energy
  • Finance
  • General
  • Medical
  • Podcasts
  • Retail
  • Technology
  • Videos

© Copyright 2022 publicwire.com

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.